Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Friedberg

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2007
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804N L Bartlett, D Niedzwiecki, J L Johnson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2008
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphomaJ H Mendler, J Kelly, S Voci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2015
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†C Casulo, B Day, K L Dawson, et al.
Seminars in Oncology|February 24, 2005
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary reportG L Phillips, C N Abboud, S H Bernstein, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 28, 1999
Autologous bone marrow transplantation after histologic transformation of indolent B cell malignanciesJ W Friedberg, D Neuberg, J G Gribben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2007
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphomaJ P Leonard, J W Friedberg, A Younes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practicesA K Nooka, C Nabhan, X Zhou, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2007
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804N L Bartlett, D Niedzwiecki, J L Johnson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2008
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphomaJ H Mendler, J Kelly, S Voci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2015
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†C Casulo, B Day, K L Dawson, et al.
Seminars in Oncology|February 24, 2005
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary reportG L Phillips, C N Abboud, S H Bernstein, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 28, 1999
Autologous bone marrow transplantation after histologic transformation of indolent B cell malignanciesJ W Friedberg, D Neuberg, J G Gribben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2007
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphomaJ P Leonard, J W Friedberg, A Younes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practicesA K Nooka, C Nabhan, X Zhou, et al.
Pageof 2